Drugs in Treating Urinary Schistosomiasis

Urinary schistosomiasis caused by trematodes of the genus Schistosoma known as Schistosoma haematobium. Schistosoma haematobium, also known to be “urinary blood fluke” that inhabits and multiplies eggs in the small venules of the perivesical and portal systems. Urinary schistosomiasis is endemic in 53 countries in Africa and the Middle East. A cholinesterase inhibitor Metrifonate is another selective treatment for SH; it has good efficacy and safety properties. Although it is economic, causes low recurrence rates. Metrifonate is that a prophylactic dose which is needed within two years to guard against recurrence. Niridazole is also highly effective for treating schistosomiasis, and a single dose of niridazole daily has a high cure rate.

  • In vitro studies
  • Albendazole Treatment
  • Egg Reduction Rate

Related Conference of Drugs in Treating Urinary Schistosomiasis

August 16-16, 2021

3rd World Conference on Vaccine and Immunology

Dubai, UAE
August 27-28, 2021

5th International Conference on Emerging Infectious Diseases

Amsterdam, Netherlands
September 30-30, 2021

11th International Conference on Bacteriology and Infectious Diseases

Cape Town, South Africa
October 12-13, 2021

International Conference on Vaccine and Vaccine research

Manila, Philippines
October 14-15, 2021

13th Annual Conference on Clinical Immunology

Cape Town, South Africa
November 04-05, 2021

9th World Summit on Immunology & Immunotherapy

Prague, Czech Republic
November 08-09, 2021

International Conference on Immunology Research

Las Vegas, USA
February 07-08, 2022

International Conference on Vaccine Research

Paris, France
March 21-22, 2022

36th International Conference on Immunology

Rome, Italy
March 21-22, 2022

15th Global Summit on Immunology and Cell Biology

Tokyo, Japan

Drugs in Treating Urinary Schistosomiasis Conference Speakers

Recommended Sessions

Related Journals

Are you interested in